Mn Services Vermogensbeheer B.V. Has $10.70 Million Holdings in IDEXX Laboratories, Inc. (IDXX)

Mn Services Vermogensbeheer B.V. lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.8% in the first quarter, HoldingsChannel.com reports. The fund owned 47,847 shares of the company’s stock after selling 400 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in IDEXX Laboratories were worth $10,699,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. LS Investment Advisors LLC boosted its position in shares of IDEXX Laboratories by 1.3% during the first quarter. LS Investment Advisors LLC now owns 3,424 shares of the company’s stock worth $766,000 after purchasing an additional 45 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in shares of IDEXX Laboratories by 4.7% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,192 shares of the company’s stock worth $222,000 after purchasing an additional 54 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its position in shares of IDEXX Laboratories by 1.8% during the fourth quarter. Oppenheimer Asset Management Inc. now owns 3,131 shares of the company’s stock worth $583,000 after purchasing an additional 56 shares in the last quarter. Security Asset Management boosted its position in shares of IDEXX Laboratories by 0.4% during the fourth quarter. Security Asset Management now owns 15,245 shares of the company’s stock worth $2,836,000 after purchasing an additional 60 shares in the last quarter. Finally, SignalPoint Asset Management LLC boosted its position in shares of IDEXX Laboratories by 5.1% during the fourth quarter. SignalPoint Asset Management LLC now owns 1,345 shares of the company’s stock worth $250,000 after purchasing an additional 65 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have recently weighed in on IDXX shares. BidaskClub raised shares of IDEXX Laboratories from a “sell” rating to a “hold” rating in a research report on Thursday, January 24th. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $236.00 price target on the stock in a research report on Monday, February 4th. Finally, Canaccord Genuity reduced their price target on shares of IDEXX Laboratories from $255.00 to $254.00 and set a “buy” rating on the stock in a research report on Tuesday, March 26th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. IDEXX Laboratories presently has a consensus rating of “Buy” and an average price target of $253.50.



In related news, insider Michael Lane sold 971 shares of the business’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of $208.00, for a total value of $201,968.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Chairman Jonathan W. Ayers sold 28,000 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $249.02, for a total transaction of $6,972,560.00. The disclosure for this sale can be found here. Insiders sold a total of 62,573 shares of company stock worth $14,641,141 over the last ninety days. 2.70% of the stock is currently owned by insiders.

IDXX opened at $242.62 on Tuesday. The firm has a market capitalization of $21.32 billion, a P/E ratio of 56.95 and a beta of 0.97. IDEXX Laboratories, Inc. has a 12 month low of $176.11 and a 12 month high of $256.22. The company has a current ratio of 1.01, a quick ratio of 0.74 and a debt-to-equity ratio of 14.81.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $1.17 EPS for the quarter, beating the consensus estimate of $1.04 by $0.13. The business had revenue of $576.06 million for the quarter, compared to analysts’ expectations of $575.04 million. IDEXX Laboratories had a net margin of 17.33% and a return on equity of 354,783.84%. The firm’s revenue was up 7.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.01 EPS. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 4.82 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Mn Services Vermogensbeheer B.V. Has $10.70 Million Holdings in IDEXX Laboratories, Inc. (IDXX)” was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://dakotafinancialnews.com/2019/05/14/mn-services-vermogensbeheer-b-v-has-10-70-million-holdings-in-idexx-laboratories-inc-idxx.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

See Also: Consumer Price Index (CPI)

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.